Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GALR2 | O43603 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953011 | 0.89 | MAPT (0.51) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL2557081 | 0.89 | MAPT (0.51) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL5069542 | 0.88 | MAPT (0.54) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL11252461 | 0.87 | MAPT (0.50) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL405164 | 0.87 | MAPT (0.50) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL29447084 | 0.85 | MAPT (0.49) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL1511509 | 0.85 | MAPT (0.49) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL4346832 | 0.85 | MAPT (0.49) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL31256155 | 0.84 | MAPT (0.47) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL2416517 | 0.84 | NPSR1 (0.47) | MAPTNPSR1HTTKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6399642-B2 | TRIS BENZIMIDAZOLES; FUNGICIDES, ANTICARCINOGENIC AGENTS, ENZYME INHIBITOR | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2002-06-04 | — | — | US | disclosed |
| US-20010009919-A1 | Heterocyclic topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2001-07-26 | — | — | US | disclosed |
| US-6221892-B1 | Heterocyclic topoisomerase poisons | THE STATE OF UNIVERSITY OF NEW JERSEY, RUTGERS | 2001-04-24 | — | — | US | disclosed |
| EP-1054870-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6063801-A | Heterocyclic topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1999041241-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-08-19 | — | — | WO | disclosed |
| US-4355030-A | Antiviral combinations | ELI LILLY AND COMPANY (US) | 1982-10-19 | — | — | US | disclosed |
| US-4289773-A | ETHYL 6,7-DIBROMO-3,4-DIHYDRO-3-OXOQUINOXALINE CARBOXYLATE AND A HINDERED AMINE | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| EP-0029658-A1 | Salts of dihalo-2-quinoxaline carboxylic acids, their preparation and pharmaceutical formulations containing them | ELI LILLY AND COMPANY (US) | 1981-06-03 | — | — | EP | disclosed |
| US-4271162-A | ETHYL 6,7-DICHLORO-3,4-DIHYDRO-3-ONOQUINOXALINE CARBOXYLATE AND 1-AMINOADAMANTANE | ELI LILLY AND COMPANY (US) | 1981-06-02 | — | — | US | disclosed |
| US-4264600-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-04-28 | — | — | US | disclosed |
| US-4252954-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
| EP-0020836-A1 | Antiviral combinations | ELI LILLY AND COMPANY (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4210647-A | INFLUENZA VIRUS, ETHYL 6,7-DIBROMO-3,4-DIHYDRO-3-OXO-2-QUINOXALINECARBOXYLATE, 1-AMINOADAMANTANE | ELI LILLY AND COMPANY (US) | 1980-07-01 | — | — | US | disclosed |
| EP-0010426-A1 | Pharmaceutical composition containing 3,4-dihydro-3-oxo-2-quinoxalines, novel such quinoxalines and processes for the production thereof | ELI LILLY AND COMPANY (US) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009919-A1 | Heterocyclic topoisomerase poisons | TOP1, TOP2A, TOP2B | MAPT 3332/4885NPSR1 4090/4885HTT 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.